Evidence map›Paper›PMID 40535153›Full record

ArticleFrontiers in cardiovascular medicine2025

Interplay of

Xingyu Cao, Huawei Wang, Zunsong Hu, Wenfang Ma, Peng Ding, Huang Sun, Xiying Guo

Abstract read
In one paragraph

Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xingyu CaoDepartment of Cardiology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Huawei WangDepartment of Cardiology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Zunsong HuDepartment of Computational and Quantitative Medicine, Beckman Research Institute of City of Hope, Duarte, CA, United States.
Wenfang MaDepartment of Cardiology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Peng DingDepartment of Cardiology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Huang SunDepartment of Cardiology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Xiying GuoDepartment of Cardiology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hypertrophic Cardiomyopathy (HCM) is an inherited heart disease and the pathogenesis of HCM involves genetic mutations, hemodynamic stress, and metabolic factors, with myocardial fibrosis playing a crucial role in severe clinical events. IL-33/ST2 signaling pathway known for its roles in immune response and tissue repair, participates in cardiac protection and anti-cardiac fibrosis in heart failure. The role of Methods: We re-analyzed RNA sequencing data from 9 high-throughput sequencing datasets comprising myocardial tissue samples from 109 HCM patients and 210 non-HCM controls. Differential gene expression analysis, correlation analyses, and Gene Set Enrichment Analysis (GSEA) were employed to explore the biological significance of Results: Our analysis identified 2,660 upregulated and 403 downregulated genes for HCM in the combined dataset, with significant downregulation of the Conclusions: Our findings suggest that downregulation of

Indexed as

hypertrophic cardiomyopathy (HCM)inflammationmyocardial fibrosisRNA sequencingST2

Identifiers

PMID40535153
PMCPMC12174446

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.